Skip to main content
Download PDF

Correlation of serum complement factor 5a level with inflammatory response and cognitive function in patients with Alzheimer’s disease of different severity

BMC Neurology volume 23, Article number: 319 (2023) Cite this article

A Correction to this article was published on 02 October 2023

This article has been updated

Abstract

Background

Alzheimer’s disease (AD) is a common cause of dementia. Serum complement factor 5a (C5a) is exceedingly implicated in AD. We explored the role of C5a levels in AD patients of different severity.

Methods

Mild, moderate, and severe AD patients, and healthy controls were included. C5a and pro-inflammatory factor (TNF-α, IL-1β, IL-6, CRP) levels were assessed by ELISA, and cognitive function was evaluated by Mini-Mental state examination (MMSE) score. The correlations between C5a, inflammatory factor levels, MMSE score, and plasma Aβ42/Aβ40 ratio were analyzed by Pearson tests. Independent risk factors for AD aggravation were assessed by logistic multivariate regression analysis. According to the cut-off value of receiver operating characteristic (ROC) curve analysis of C5a level, AD patients were assigned into low/high expression groups, and severe AD incidence was compared. Severe AD cumulative incidence was analyzed by Kaplan-Meier curve.

Results

Serum C5a, TNF-α, IL-1β, IL-6 and CRP levels were raised, and MMSE score was lowered in AD. Serum C5a, TNF-α, IL-1β, IL-6 and CRP levels in severe AD patients were higher than those in mild/moderate AD patients, but there were no significant differences in these cytokines between moderate and mild AD groups. The MMSE score of severe AD patients was lower than that of mild/moderate AD patients. Serum C5a level was positively correlated with serum TNF-α, IL-1β, IL-6, and CRP levels, and negatively correlated with MMSE score, with no obvious correlation with plasma Aβ42/Aβ40 ratio. Serum C5a level was one of the independent risk factors for AD aggravation. The occurrence of severe AD might be related to an increase in serum C5a level.

Conclusion

Serum C5a level increased with AD severity, and its expression was positively correlated with serum pro-inflammatory factor levels, and negatively correlated with cognitive function.

Peer Review reports

Introduction

Alzheimer’s disease (AD) is a complex neurodegenerative disease, which is characterized by neuron progressive loss, typically causing severe impairment in cognitive functions of patients including memory and learning [1]. Nowadays, as the most prevalent cause of dementia, AD is a growing health concern across the globe, with huge implications for society and individuals [2]. The majority of AD is multifactorial with complex interactions across polygenic risk factors (especially apolipoprotein E), lifestyle, and environmental factors [3]. Neurodegeneration (such as neuronal loss and/or atrophy) can be attributed to intraneuronal neurofibrillary tangles consisting of hyperphosphorylated tau, extraneuronal toxic amyloid proteins and oligomers, region-specific repressed cerebral glucose metabolism, mitochondrial dysfunction, and synaptic dysfunction [4]. The 2 central pathological hallmarks of AD are neurofibrillary tangles and amyloid plaques, and the deposition of amyloid β (Aβ) triggers dysfunction of neurons and death in the brain [5]. The 3 identified (classic) biomarkers in cerebrospinal fluid (CSF) are Aβ42, tau protein phosphorylated at a threonine residue at position 181 (τP-181), and total tau protein (τT), which are the gold standards for liquid based diagnosis of AD [6, 7]. Through a better understanding of AD inflammation, it is possible to develop anti-inflammatory approaches, which are likely help to slow the progression of this devastating disease [8]. Therefore, it is pivotal to study the mechanism of AD through the aspect of inflammation and find efficient targets for AD alleviation.

Blood based biomarkers as a possible diagnostic aid for CSF biomarker have recently received widespread attention [9]. Blood sampling is an easy, non-invasive, and acceptable procedure without complications, requiring no hospitalization, and can be performed in outpatient wards or communities, which allows for the collection of larger sample sizes and is suitable for a wider range of analyte measurements [10]. The complement system is an extremely pivotal component of the innate immune system with the ability to identify and clear infectious challenges that invade the central nervous system through damaged blood-brain barriers, which has an essential property in the defense of the host to ultimately maintain the homeostasis of the brain, and multiple complement proteins have been identified to be co-localize with amyloid plaques in AD patients, indicating a role of the in AD [11, 12]. The activation of the complement system plays an important role in AD neuroinflammatory injury, and the complement mainly exists in serum and tissue fluid, and activated complement can have enzymatic activity [13]. A previous study has recognized the involvement of complement cascade in the pathogenesis of AD, with high levels of complement produced in the affected areas of the AD brains, and the complete activation of the classical complement pathway may have a significant impact on the pathology of AD [14]. Complement proteins and many inflammatory mediators are locally produced by brain cells [15]. Complement activation in the central nervous system is a double-edged sword. Brain complement activation may promote tissue damage by inducing neuronal cell death (allergic toxins and membrane attacks) and promote the release of pro-inflammatory cytokines by activated glial cells. On the other hand, complement activation can have beneficial effects on the brains by promoting neuroprotection and tissue remodeling [16]. Excessive downstream complement activation leads to the generation of C5a, and C5a engages with its receptor C5aR1 to trigger inflammation, injury, and neuronal death [17]. C5a induces neuronal cell apoptosis, while C5a/C5aR1 signaling increases vascular permeability and the production of inflammatory cytokines [18]. Complement protein C5a promotes the β-amyloid-mediated neuroinflammatory response in microglia in AD [19]. The life of C5a is brief, and it rapidly transforms into C5a-des Arg in the body [20]. C5a receptors (C5aR1) is the pro-inflammatory receptor for C5a, and the C5aR1 antagonist beneficial effects in AD mice may be due to neuron protection from the toxic effects of C5a [21]. The apoptosis pathway is associated with C5aR [22]. The C5aR-mediated pathway may be involved in neurodegenerative lesions of AD, and abnormal activation of this signaling pathway can lead to cell apoptosis, leading to neurodegenerative diseases [23, 24]. These studies all indicate the relationship between neuronal C5a and AD progression. However, there are few reports on the changes in serum C5a levels in patients with AD of different severity and its correlation with inflammatory response and cognitive function. This study investigated the changes in serum C5a levels in patients with AD of different severity, and analyzed their relationship with inflammatory factors and cognitive function, so as to provide references for clinical prevention and treatment in AD.

Materials and methods

Ethics statement

The experiments were authorized by the academic ethics committee of the First People´s Hospital of Jingzhou City. All procedures were strictly implemented according to Declaration of Helsinki. All subjects involved were fully informed of the study objective and signed the informed consent before sampling.

Study subjects

AD patients diagnosed in the First People’s Hospital of Jingzhou City from July 2019 to June 2021 were treated to improve their cognitive function and enhance their behavioral and life abilities, and 240 AD patients who met the requirements were selected as the study subjects, including 107 males and 133 females, aged 58–85 years. All participants underwent clinical interviews and related neurocognitive assessments, as well as necessary laboratory or imaging examinations. According to the clinical dementia rating scale (CDR) score, AD patients were assigned to 3 subgroups: mild group (CDR score 1, 78 cases), moderate group (CDR score 2, 85 cases), and severe group (CDR score 3, 77 cases). Another 80 healthy subjects who underwent physical examinations in the First People’s Hospital of Jingzhou City during the same period were selected as the control group, including 37 males and 43 females, aged 58–85 years. AD was diagnosed based on the core clinical standards of The National Institute on Aging and the Alzheimer’s Association [25]. The CDR score was strictly executed according to the standards, and was operated by trained physicians. There was a semi-structured interview between the operator and the patients, where the physician asked the patient 6 questions, scored them based on the their response, and asked the informed or caregivers to understand the patient’s daily living conditions.

Inclusion and exclusion criteria

Inclusion criteria were as follows: (1) meeting the diagnostic criteria of AD; (2) with decreased cognitive function, executive function, and motor control; (3) with complete Mini-Mental State Examination (MMSE) data.

Exclusion criteria were as follows: (1) with infectious or inflammatory diseases; (2) with immune system diseases; (3) with brain diseases such as intracranial space occupying, brain trauma, epilepsy, or cerebrovascular diseases; (4) with Lewy body dementia, vascular dementia, and other cognitive impairment [with the aid of positron emission tomography (PET) imaging, Lewy body dementia was diagnosed by the reduction of dopamine transporter (DAT) uptake; vascular dementia was diagnosed according to the DSM-IV diagnostic criteria, and could also be examined through CT or MRI imaging]; (5) with severe heart, liver and kidney failure; (6) with drug-induced, toxic, hypothyroidism, and other secondary dementia; (7) with anxiety, depression, schizophrenia, and other mental diseases; (8) with malignant tumor disease.

Data and sample collection

The following clinical baseline data of selected subjects were collected: age, sex (male/female), body mass index (BMI), disease duration, education level, smoking history, drinking history, diabetes, hypertension, systolic blood pressure (SBP), diastolic blood pressure (DBP), and MMSE data. Serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels were determined using a fully automatic biochemical analyzer in strict accordance with the product instructions, by the same batch of personnel from the laboratory on the same instrument, with each sample repeated 3 times. MMSE can assess the cognitive function of patients, including 5 tasks: registration (3 scores), orientation (10 scores), recall (3 scores), attention and calculation (5 scores), and language (9 scores), with a total score of 30. A lower total score represented worse cognitive function [26]. On the next morning, 10 mL of fasting venous blood of each enrolled patient after admission was collected into an ordinary blood collection tubes without anticoagulant, and 6 mL of venous blood was collected, allowed to stand for 30 min, and centrifuged for 10 min at 4 °C at 3000 r/min, and the supernatant was collected for subpackage in eppendorf (EP) tubes, labeled, and stored at a refrigerator at -80 °C. The rest 4 mL of venous blood was placed in the ethylenediaminetetraacetic acid anticoagulant tubes, allowed to stand, centrifuged, and the plasma was collected for subpackage in EP tubes, labeled, and stored at -80 °C.

Enzyme-linked immunosorbent assay (ELISA)

The serum C5a level and serum inflammatory factors including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, C-reactive protein (CRP) levels, and plasma Aβ40, Aβ42 levels were assessed using the ELISA kit (Amylet Scientific, Wuhan, Hubei, China), and the Aβ42/Aβ40 value was calculated. The operations were conducted according to kit instructions.

Statistical analysis

GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA, USA) and SPSS 21.0 (IBM Corp. Armonk, NY, USA) were adopted for data analysis and mapping. Shapiro-Wilk test was employed for normal distribution test. Data were expressed as mean ± standard deviation, with non-paired t test applied for comparisons between 2 groups, and one-way analysis of variance (ANOVA) applied for comparisons among groups, followed by Tukey’s multiple comparisons test. Fisher’s exact test was adopted for comparative analysis of categorical variables. Logistic multivariate regression analysis was employed to evaluate the independent risk factors for AD exacerbation. The diagnostic value of serum C5a level in AD patients was analyzed using the receiver operating characteristic (ROC) curve. Kaplan-Meier curve was used to analyze the effect of serum C5a level on the cumulative incidence of severe AD. P < 0.05 was indicative of statistical significance.

Results

Comparisons of general clinical data of AD patients with different severity

A total of 320 subjects were included in this study, including 80 healthy subjects (Non-AD group), 78 patients with mild AD, 85 patients with moderate AD, and 77 patients with severe AD. Comparative analysis of clinical data of mild, moderate and severe AD groups and Non-AD group manifested that there were no significant differences among the 4 groups in sex, BMI, disease duration, educational level, smoking and drinking history, diabetes, hypertension, SBP, DBP, TC, TG, LDL, and HDL levels (all P > 0.05), while there were statistical differences between mild AD and Non-AD groups, and among the mild, moderate and severe groups in age (all P < 0.05). In addition, there was statistical difference in Aβ42/Aβ40 ratio between severe AD and mild AD groups, and among moderate, severe groups and Non-AD group (all P < 0.05) (Table 1).

Table 1 Comparisons of general clinical data of AD patients of different severity
Full size table

Comparison of serum C5a, pro-inflammatory factors and MMSE scores in AD patients with different severity and healthy subjects

Serum C5a and pro-inflammatory factor (TNF-α, IL-1β, IL-6, CRP) levels in AD patients with different severity and Non-AD group were determined by ELISA. Serum C5a, TNF-α, IL-1β, IL-6 and CRP levels in AD group was higher than those of the Non-AD group (all P < 0.05). Among them, patients with severe AD manifested elevated C5a level relative to the mild and moderate groups (all P < 0.05), while no significant difference between the moderate AD group and the mild AD group (P = 0.122). TNF-α, IL-1β, IL-6, and CRP levels between the severe AD group and the mild and moderate AD groups were statistically significant (all P < 0.05), while TNF-α, IL-1β, IL-6, and CRP levels between the mild AD group and the moderate AD group were not significantly different (P = 0.055, 0.067, 0.093, 0.088). Additionally, the MMSE score of the AD group was lower than those of the Non-AD group (all P < 0.05). There was a statistically significant difference in MMSE score between the severe AD group and the mild and moderate AD groups and also between the mild and moderate AD groups (all P < 0.05) (Table 2).

Table 2 Comparisons of serum C5a, pro-inflammatory factors, and MMSE scores between AD patients of different severity and healthy subjects
Full size table

Correlation analysis of serum C5a level with pro-inflammatory factors, MMSE scores and Aβ42/Aβ40 ratio in AD patients

To further explore the relationship between serum C5a level, inflammatory factor level, and cognitive function in AD patients, the correlation of serum C5a level with inflammatory factor (TNF-α, IL-1β, IL-6, CRP) and MMSE score was analyzed by Pearson test. Serum C5a level was positively correlated with TNF-α, IL-1β, IL-6, and CRP levels (r = 0.369, 0.262, 0.297, 0.456) (all P < 0.001) (Fig. 1A-D), and was negatively correlated with the MMSE score (r = -0.427) (P < 0.001) (Fig. 1E). In addition, there was no significant correlation between plasma Aβ42/Aβ40 ratio and serum C5a level (r = 0.053) (P > 0.05) (Fig. 1F). The results indicated that serum C5a level was not affected by Aβ accumulation, and was closely associated with serum pro-inflammatory factors, which could reflect the inflammatory state of the body to a certain extent, and could reflect the cognitive function of AD patients.

Fig. 1
figure 1

Correlation analysis of serum C5a level with pro-inflammatory factors, MMSE scores and Aβ42/Aβ40 ratio. (A-E) The correlations between serum C5a level and pro-inflammatory factors (TNF-α, IL-1β, IL-6, CRP) and the MMSE score were analyzed by Pearson test. (F) Correlation analysis between plasma Aβ42/Aβ40 ratio and serum C5a level. Data in panels A-F were analyzed by Pearson coefficient

Full size image

Serum C5a level is one of the independent risk factors for the exacerbation in AD patients

To further explore the relationship between serum C5a level and the severity of AD patients, AD severity was taken as the dependent variable, and age, TNF-α, IL-1β, IL-6, CRP, and serum C5a levels were included in the binary logistic regression analysis model combining with the previous analysis results. After adjusting age, IL-1β and CRP levels, serum C5a level was on of the independent risk factors for AD aggravation (P = 0.001, OR = 1.070, 95%CI: 1.027–1.115) (Table 3).

Table 3 Logistic multivariate regression analysis of risk factors for the aggravation of AD patients
Full size table

The occurrence of severe AD might be related to a stimulated serum C5a level

Firstly, serum C5a level in severe, moderate and mild AD groups was compared (P < 0.05) (Fig. 2A). ROC curve of serum C5a level for AD severity assessment was plotted (Fig. 2B). The area under the curve (AUC) was 0.761, and the cut-off value was 65.78 pg/mL (sensitivity 100.00%, specificity 39.88%), indicating that serum C5a level > 65.78 pg/mL assisted in the diagnosis of severe AD patients. In addition, AD patients were allocated to the low C5a expression group (C5a < 65.78pg/mL, N = 72) and high C5a expression group (C5a ≥ 65.78 pg/mL, N = 168) based on the cut-off value of ROC curve analysis of serum C5a level. The incidence of severe AD was compared between the 2 groups. There were differences in the incidence of severe AD between the 2 groups (χ2 = 7.540, P < 0.05). The incidence of severe AD in the high C5a expression group was 37.50% (63/168), higher than that in the low C5a expression group (14/72, 19.44%) (Table 4). Moreover, Kaplan-Meier curve analysis manifested that the curve of the C5a overexpression group shifted to the left (P < 0.05, Fig. 2C), indicating that the cumulative incidence of severe AD in the C5a overexpression group was higher under the same evaluation cycle. The results indicated that the occurrence of severe AD might be associated with a facilitated serum C5a level.

Fig. 2
figure 2

The difference of serum C5a level between mild, moderate and severe AD patients. (A) Serum C5a level was determined by ELISA; (B) The ROC curve of serum C5a level for severe AD evaluation; (C) Kaplan-Meier curve was employed to analyze the cumulative incidence of severe AD. Data in panel A were tested by independent t test. Data in panel B were analyzed using the ROC curve. * P < 0.05

Full size image
Table 4 Prognosis of high and low serum C5a expression groups
Full size table

Discussion

AD is the most prevalent cause of dementia, which is a growing global health problem with huge implications for both society and individuals [2]. Evidence has shown that C5a can interfere with neuropathologic and neuroinflammation alterations in AD mouse models [27]. This study investigated the changes in serum C5a levels in AD patients with different severity and found that serum C5a level was augmented with the severity of AD, and its expression was positively correlated with serum pro-inflammatory factor levels, and negatively correlated with cognitive function.

An existing study has reported that the peripheral immune system is believed to affect the pathology of the central nervous system in AD, and the peripheral adaptive immune response, especially T cell-mediated peripheral adaptive immune response, may play a role in the pathogenesis of AD [28]. In addition, blood biomarkers have high specificity and sensitivity, which, as newly developed biomarkers, can identify various pathological processes, including neuroinflammation, synaptic dysfunction, metabolic damage, protein aggregation, and neurodegeneration [29]. Therefore, non-invasive and easily obtainable peripheral inflammatory biomarkers should be considered as potential biomarkers for early diagnosis of AD. The complement system, as an important component of the innate immune system, plays an important role in the inflammatory damage of AD nerve after activation. Therefore, measurement of serum C5a levels can reflect the condition of AD disease and has important clinical significance. Accumulating data support that the essential AD CSF biomarker Aβ42 reflects key elements of the pathophysiology of AD [6]. Our results revealed that mild AD patients and non-AD subjects, and mild, moderate and severe AD patients manifested statistical differences in age and Aβ42/Aβ40 ratio. Consistently, disease-linked mutations in presenilin genes cause stimulated production Aβ42, which is the predominant form found in AD [30]. The complement system is a main component of inflammatory responses, which may have a crucial property in neurodegenerative conditions including AD [31]. Our results manifested that the serum levels of C5a, TNF-α, IL-1β, IL-6 and CRP in AD patients were higher than those of the non-AD subjects, with the levels in severe AD patients facilitated compared with those of mild and moderate AD patients, while there was no significant differences in these levels between mild and moderate AD patients. Likewise, C5a is a potent effector of microglial movement, which is up-regulated in a variety of neurodegenerative diseases, including AD [32, 33]. C5a-C5aR1 signaling largely exerts its functions in AD by promoting microglial activation pathways, which accelerate the progression of the disease [17]. However, there is a little report on serum C5a levels in AD patients of different severity. This study manifested for the first time that C5a level was intensified with the severity of AD. Inflammation exists in the pathologically vulnerable regions of AD brains, which is related to the full complexity of the local peripheral inflammatory responses [34]. Serum inflammation status is evaluated by TNF-α, IL-1β, IL-6, and CRP [35]. Our results elicited that severe AD patients had statistical differences in TNF-α, IL-1β, IL-6, and CRP levels with mild and moderate AD patients. Similarly, pro-inflammatory cytokine TNF-α is related to agitation severity in AD [36] and IL-1β is implicated in contributing to disease severity in various central nervous system diseases including AD [37]. MMSE score is the most commonly used scale to assess cognitive impairment [38]. Our findings elicited that AD patients demonstrated lowered MMSE scores relative to the non-AD subjects, with statistical difference in MMSE scores between severe and moderate AD patients, and no statistical difference between mild and moderate AD patients.

Complement activation in the central nervous system is a double-edged sword. Brain complement activation may promote tissue damage by inducing neuronal cell death and promoting the release of pro-inflammatory cytokines through activated glial cells. On the other hand, complement activation can have beneficial effects on the brain by promoting neuroprotection and tissue remodeling [16]. Complement system activation plays an important role in AD neuroinflammatory injury. Complements in serum are generally secreted by macrophages, neutrophils, natural killer cell, dendritic cells and other immune cells. Complements in the central nervous system are mainly produced by activation of microglia [31, 39]. Complement C5a is produced in the process of complement activation, which can strongly attract neutrophils, astrocyte and microglia in the brain to gather in the area of complement activation, and has a strong function of promoting inflammation [40]. Therefore, determination of serum C5a level can reflect the inflammatory state of the body to a certain extent. Repressing the activation of the complement system can reduce the induction of inflammatory factors by diminishing the level of C5a, thus reducing the release of inflammatory factors, which has certain value in preventing and treating AD. Therefore, assessing serum C5a level has certain clinical significance in AD. Our research showed that serum C5a level was the independent risk factors for worsening AD, and high C5a level was the risk factor for severe AD. Subsequently, we analyzed correlations of serum level of C5a with pro-inflammatory factors, MMSE score, and Aβ42/Aβ40 ratio and found a positive correlation between serum level of C5a and the levels of TNF-α, IL-1β, IL-6, and CRP, and a negative correlation between serum level of C5a and MMSE score. However, previous study has shown that complement can be activated by Aβ [41]. Importantly, C5a can also synergistically exert damaging effects with Aβ, causing neurological deficits [42].To exclude the possibility that high level of serum C5a might be considered as a result of a accumulation, we found no significant correlation between plasma Aβ42/Aβ40 ratio and serum C5a level through Pearson correlation analysis (correlation coefficient r = 0.053, P > 0.05), which could prove that high level of C5a in the blood was not the result of Aβ accumulation. Similarly, activation of complement proteins mediates the expression of chemokines and pro-inflammatory cytokines (such as IL-1 and TNF-α) [43]. Complement protein induces cognitive decline and neuroinflammation after traumatic brain injury at extended chronic time points [44]. Collectively, serum level of C5a was not influenced by plasma Aβ42/Aβ40 ratio, and was closely related to serum pro-inflammatory factors, which reflected the inflammatory state and cognitive function of AD patients. Furthermore, through logistic regression analysis, we discovered that after age, IL-1β, and CRP level adjustment, serum level of C5a was one of the independent risk factors for AD aggravation. Similarly, complement receptor 1 gene variation is identified in recent studies as a risk factor for AD [45]. To conclude, augmented serum levels of C5a promoted the risk of AD exacerbation. Moreover, we plotted ROC curves and found that serum level of C5a > 65.78 pg/mL assisted in severe AD diagnosis and discovered for the first time that the occurrence of severe AD might be associated with an amplified serum C5a level.

In summary, our findings supported that serum C5a level was one of the independent risk factors for AD exacerbation, which pave the way for the clinical treatment of AD. The activation of the complement system plays a crucial role in the neuroinflammatory injury of AD. However, we only preliminarily discussed the correlations between C5a level change and inflammatory response and cognitive function in AD patients with different severity but did not deeply explore the role of C5a level in the pathogenesis of AD. Moreover, the specific relationship between C5a and cognitive function of AD patients was not studied in depth. Additionally, the number of cases and events included in this study for analysis is relatively small, and further expansion of sample size and multicenter studies are needed to further clarify the clinical significance of serum C5a level in AD. Furthermore, due to the limitations in experimental period and funding, we are currently unable to obtain a sufficient sample size for other dementia patients (non AD patients) to verify the results of serum C5a level. Furthermore, measuring peripheral blood indicators may not necessarily reflect the internal situation of the brain, and serum C5a may be influenced by various factors such as coagulation processes, which needs further study to explore the correlation between severe AD and serum C5a levels in multiple aspects. These deficiencies need to be supplemented in future studies to clarify the relationship between C5a and inflammation from the molecular and cellular levels.

Data availability

All the data generated or analyzed during this study are included in this published article.

Change history

Abbreviations

AD:

Alzheimer’s disease

C5a:

Complement factor 5a

MMSE:

Mini-Mental state examination

ROC:

Receiver operating characteristic

Aβ:

Amyloid β

CDR:

Clinical dementia rating scale

BMI:

Body mass index

SBP:

Systolic blood pressure

DBP:

Diastolic blood pressure

TC:

Total cholesterol

TG:

Triglycerides

LDL:

Low-density lipoprotein

HDL:

High-density lipoprotein

ELISA:

Enzyme-linked immunosorbent assay

TNF-α:

Tumor necrosis factor-α

IL:

Interleukin

CRP:

C-reactive protein

ANOVA:

Analysis of variance

References

  1. Fakhoury M. Microglia and astrocytes in Alzheimer’s Disease: implications for Therapy. Curr Neuropharmacol. 2018;16 5:508–18. https://doi.org/10.2174/1570159X15666170720095240.

    Article  Google Scholar 

  2. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25 1:59–70. https://doi.org/10.1111/ene.13439.

    Article  Google Scholar 

  3. Eratne D, Loi SM, Farrand S, Kelso W, Velakoulis D, Looi JC. Alzheimer’s disease: clinical update on epidemiology, pathophysiology and diagnosis. Australas Psychiatry. 2018;26 4:347–57. https://doi.org/10.1177/1039856218762308.

    Article  Google Scholar 

  4. Oboudiyat C, Glazer H, Seifan A, Greer C, Isaacson RS. Alzheimer’s disease. Semin Neurol. 2013;33 4:313–29. https://doi.org/10.1055/s-0033-1359319.

    Article  Google Scholar 

  5. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet. 2011;377 9770:1019–31. https://doi.org/10.1016/S0140-6736(10)61349-9.

    Article  Google Scholar 

  6. Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;284 6:643–63. https://doi.org/10.1111/joim.12816.

    Article  Google Scholar 

  7. McGrowder DA, Miller F, Vaz K, Nwokocha C, Wilson-Clarke C, Anderson-Cross M, et al. Cerebrospinal fluid biomarkers of Alzheimer’s Disease: current evidence and future perspectives. Brain Sci. 2021;11(2). https://doi.org/10.3390/brainsci11020215.

  8. Ozben T, Ozben S. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease. Clin Biochem. 2019;72:87–9. https://doi.org/10.1016/j.clinbiochem.2019.04.001.

    Article  CAS  PubMed  Google Scholar 

  9. Zetterberg H, Blennow K. Blood biomarkers: democratizing Alzheimer’s Diagnostics. Neuron. 2020;106 6:881–3. https://doi.org/10.1016/j.neuron.2020.06.004.

    Article  CAS  Google Scholar 

  10. Tzartos JS, Boufidou F, Stergiou C, Kuhle J, Willemse E, Palaiodimou L, et al. Plasma P-Tau181 for the discrimination of Alzheimer’s Disease from other primary dementing and/or Movement Disorders. Biomolecules. 2022;12:8. https://doi.org/10.3390/biom12081099.

    Article  CAS  Google Scholar 

  11. Gomez-Arboledas A, Carvalho K, Balderrama-Gutierrez G, Chu SH, Liang HY, Schartz ND, et al. C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimer’s disease. Acta Neuropathol Commun. 2022;10(1:116). https://doi.org/10.1186/s40478-022-01416-6.

  12. Gasque P, Neal JW, Singhrao SK, McGreal EP, Dean YD, Van BJ, et al. Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities. Mol Neurobiol. 2002;25 1:1–17. https://doi.org/10.1385/mn:25:1:001.

    Article  Google Scholar 

  13. Morgan BP. Complement in the pathogenesis of Alzheimer’s disease. Semin Immunopathol. 2018;40. https://doi.org/10.1007/s00281-017-0662-9. 1:113 – 24.

  14. Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer’s disease brain. Am J Pathol. 1999;154 3:927–36. https://doi.org/10.1016/S0002-9440(10)65340-0.

    Article  Google Scholar 

  15. McGeer PL, McGeer EG. Inflammation of the brain in Alzheimer’s disease: implications for therapy. J Leukoc Biol. 1999;65 4:409–15. https://doi.org/10.1002/jlb.65.4.409.

    Article  Google Scholar 

  16. van Beek J, Elward K, Gasque P. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci. 2003;992:56–71. https://doi.org/10.1111/j.1749-6632.2003.tb03138.x.

    Article  PubMed  Google Scholar 

  17. Carvalho K, Schartz ND, Balderrama-Gutierrez G, Liang HY, Chu SH, Selvan P, et al. Modulation of C5a-C5aR1 signaling alters the dynamics of AD progression. J Neuroinflammation. 2022;19(1:178). https://doi.org/10.1186/s12974-022-02539-2.

  18. Mahajan SD, Tutino VM, Redae Y, Meng H, Siddiqui A, Woodruff TM, et al. C5a induces caspase-dependent apoptosis in brain vascular endothelial cells in experimental lupus. Immunology. 2016;148 4:407–19. https://doi.org/10.1111/imm.12619.

    Article  CAS  Google Scholar 

  19. An XQ, Xi W, Gu CY, Huang X. Complement protein C5a enhances the beta-amyloid-induced neuro-inflammatory response in microglia in Alzheimer’s disease. Med Sci (Paris). 2018;34 Focus issue F1:116–20. https://doi.org/10.1051/medsci/201834f120.

    Article  PubMed  Google Scholar 

  20. Larsen GL, McCarthy K, Webster RO, Henson J, Henson PM. A differential effect of C5a and C5a des arg in the induction of pulmonary inflammation. Am J Pathol. 1980;100(1):179–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Hernandez MX, Namiranian P, Nguyen E, Fonseca MI, Tenner AJ. C5a increases the Injury to primary neurons elicited by fibrillar amyloid Beta. ASN Neuro. 2017;9(1:1759091416687871). https://doi.org/10.1177/1759091416687871.

  22. Farkas I, Baranyi L, Kaneko Y, Liposits Z, Yamamoto T, Okada H. C5a receptor expression by TGW neuroblastoma cells. NeuroReport. 1999;10 14:3021–5. https://doi.org/10.1097/00001756-199909290-00027.

    Article  Google Scholar 

  23. Farkas I, Baranyi L, Takahashi M, Fukuda A, Liposits Z, Yamamoto T, et al. A neuronal C5a receptor and an associated apoptotic signal transduction pathway. J Physiol. 1998;507(Pt 3):679–87. https://doi.org/10.1111/j.1469-7793.1998.679bs.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Farkas I, Takahashi M, Fukuda A, Yamamoto N, Akatsu H, Baranyi L, et al. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer’s disease. J Immunol. 2003;170 11:5764–71. https://doi.org/10.4049/jimmunol.170.11.5764.

    Article  Google Scholar 

  25. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7 3:257–62. https://doi.org/10.1016/j.jalz.2011.03.004.

    Article  Google Scholar 

  26. Salami M, Alinaghipour A, Daneshvar R, Hamidi GA, Agahi A, Soheili M, et al. Adapted MMSE and TYM cognitive tests: how much powerful in screening for Alzheimer’s disease in iranian people. Aging Ment Health. 2020;24 6:1010–7. https://doi.org/10.1080/13607863.2019.1584786.

    Article  Google Scholar 

  27. Landlinger C, Oberleitner L, Gruber P, Noiges B, Yatsyk K, Santic R, et al. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer’s disease. J Neuroinflammation. 2015;12:150. https://doi.org/10.1186/s12974-015-0369-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Xu H, Jia J, Single-Cell RNA. Sequencing of Peripheral Blood reveals Immune Cell Signatures in Alzheimer’s Disease. Front Immunol. 2021;12:645666. https://doi.org/10.3389/fimmu.2021.645666.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Guzman-Martinez L, Maccioni RB, Farias GA, Fuentes P, Navarrete LP. Biomarkers for Alzheimer’s Disease. Curr Alzheimer Res. 2019;16 6:518–28. https://doi.org/10.2174/1567205016666190517121140.

    Article  CAS  Google Scholar 

  30. Tan Y, Zhang Q, Wong SG, Hua Q. Anti-Alzheimer therapeutic drugs targeting gamma-secretase. Curr Top Med Chem. 2016;16 5:549–57. https://doi.org/10.2174/1568026615666150813144151.

    Article  CAS  Google Scholar 

  31. Goetzl EJ, Schwartz JB, Abner EL, Jicha GA, Kapogiannis D. High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann Neurol. 2018;83 3:544–52. https://doi.org/10.1002/ana.25172.

    Article  CAS  Google Scholar 

  32. Cudaback E, Li X, Montine KS, Montine TJ, Keene CD. Apolipoprotein E isoform-dependent microglia migration. FASEB J. 2011;25 6:2082–91. https://doi.org/10.1096/fj.10-176891.

    Article  CAS  Google Scholar 

  33. Tenner AJ. Complement-mediated events in Alzheimer’s Disease: mechanisms and potential therapeutic targets. J Immunol. 2020;204 2:306–15. https://doi.org/10.4049/jimmunol.1901068.

    Article  CAS  Google Scholar 

  34. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16 6:358–72. https://doi.org/10.1038/nrn3880.

    Article  CAS  Google Scholar 

  35. Bozluolcay M, Andican G, Firtina S, Erkol G, Konukoglu D. Inflammatory hypothesis as a link between Alzheimer’s disease and diabetes mellitus. Geriatr Gerontol Int. 2016;16 10:1161–6. https://doi.org/10.1111/ggi.12602.

    Article  Google Scholar 

  36. Ruthirakuhan M, Herrmann N, Andreazza AC, Verhoeff N, Gallagher D, Black SE, et al. Agitation, oxidative stress, and Cytokines in Alzheimer Disease: biomarker analyses from a clinical Trial with Nabilone for Agitation. J Geriatr Psychiatry Neurol. 2020;33 4:175–84. https://doi.org/10.1177/0891988719874118.

    Article  Google Scholar 

  37. Mendiola AS, Cardona AE. The IL-1beta phenomena in neuroinflammatory diseases. J Neural Transm (Vienna). 2018;125 5:781–95. https://doi.org/10.1007/s00702-017-1732-9.

    Article  CAS  Google Scholar 

  38. Jia X, Wang Z, Huang F, Su C, Du W, Jiang H, et al. A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in chinese middle-aged and older population: a cross-sectional study. BMC Psychiatry. 2021;21(1:485). https://doi.org/10.1186/s12888-021-03495-6.

  39. Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, et al. Complement C3aR inactivation attenuates Tau Pathology and reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer’s Disease. Neuron. 2018;100 6:1337–53e5. https://doi.org/10.1016/j.neuron.2018.10.031.

    Article  CAS  Google Scholar 

  40. Pataky R, Howie FA, Girardi G, Boardman JP. Complement C5a is present in CSF of human newborns and is elevated in association with preterm birth. J Matern Fetal Neonatal Med. 2017;30 20:2413–6. https://doi.org/10.1080/14767058.2016.1251896.

    Article  CAS  Google Scholar 

  41. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1992;89 21:10016–20. https://doi.org/10.1073/pnas.89.21.10016.

    Article  Google Scholar 

  42. Burwick RM, Togioka BM, Speranza RJ, Gaffney JE, Roberts VHJ, Frias AE, et al. Assessment of blood-brain barrier integrity and neuroinflammation in preeclampsia. Am J Obstet Gynecol. 2019;221. https://doi.org/10.1016/j.ajog.2019.06.024. 3:269 e1- e8.

  43. Prabhu SD, Frangogiannis NG. The Biological basis for Cardiac Repair after myocardial infarction: from inflammation to Fibrosis. Circ Res. 2016;119 1:91–112. https://doi.org/10.1161/CIRCRESAHA.116.303577.

    Article  CAS  Google Scholar 

  44. Mallah K, Couch C, Alshareef M, Borucki D, Yang X, Alawieh A, et al. Complement mediates neuroinflammation and cognitive decline at extended chronic time points after traumatic brain injury. Acta Neuropathol Commun. 2021;9(1:72). https://doi.org/10.1186/s40478-021-01179-6.

  45. Hamilton G, Evans KL, Macintyre DJ, Deary IJ, Dominiczak A, Smith BH, et al. Alzheimer’s disease risk factor complement receptor 1 is associated with depression. Neurosci Lett. 2012;510 1:6–9. https://doi.org/10.1016/j.neulet.2011.12.059.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Neurology, The First People´s Hospital of Jingzhou City, No.8 HangKong Road, Shashi District, 434100, Jingzhou City, Hubei Province, P.R. China

    Zhilian Li, Yi Luo & Xianpei Tan

  2. Yangtze University, 434023, Jingzhou City, Hubei Province, P.R. China

    Huifang Wu

Authors
  1. Zhilian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huifang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xianpei Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZLL and HFW is the guarantor of integrity of the entire study; YL contributed to the study concepts, study design, and definition of intellectual content; XPT contributed to the literature research; YL contributed to the manuscript preparation; ZLL and HFW contributed to the manuscript editing and review; XPT contributed to the clinical studies; YL and XPT contributed to the experimental studies and data acquisition; YL and XPT contributed to the data analysis and statistical analysis. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Huifang Wu.

Ethics declarations

Ethics approval and consent to participate

The experiments were authorized by the academic ethics committee of the First People´s Hospital of Jingzhou City. All procedures were strictly implemented according to Declaration of Helsinki. All subjects involved were fully informed of the study objective and signed the informed consent before sampling.

Consent for publication

Not applicable.

Competing interests

All authors declare that there is no competing interest in this study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: an error was reported in the affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Z., Wu, H., Luo, Y. et al. Correlation of serum complement factor 5a level with inflammatory response and cognitive function in patients with Alzheimer’s disease of different severity. BMC Neurol 23, 319 (2023). https://doi.org/10.1186/s12883-023-03256-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12883-023-03256-w

Keywords

BMC Neurology

ISSN: 1471-2377

Contact us